Familial pulmonary fibrosis (FPF) makes up a notable portion of all cases of interstitial lung disease, disorders marked by…
Articles by Steve Bryson, PhD
Vaccines based on protein fragments unique to the scar-forming cells that drive idiopathic pulmonary fibrosis (IPF) significantly reduced lung…
Treatment with GRI-0621, an experimental oral therapy from GRI Bio, boosts lung function in adults with idiopathic pulmonary…
A novel inhalable therapy has shown promise for treating idiopathic pulmonary fibrosis (IPF) by outperforming an approved oral medicine…
Blocking caspase-9 — an enzyme involved in programmed cell death, or apoptosis — may halt or reverse tissue scarring in…
Treatment with Trevi Therapeutics’ nalbuphine extended-release (ER) tablets significantly reduced daily coughing frequency in people with idiopathic pulmonary…
Let-7, an established tumor suppressor microRNA that controls gene activity, plays a key role in lung tissue repair and the…
Nerandomilast, Boehringer Ingelheim’s investigational oral therapy, significantly slowed lung function decline in people with idiopathic pulmonary fibrosis (IPF)…
A cancer immunotherapy known as ipilimumab was able to reduce scar formation and promote tissue regeneration in the lungs of…
Blocking Piezo2, a protein receptor that senses mechanical forces in tissues — ones such as stress, strain, and stiffness —…